Polygenic Risk Factors for Comorbid Diagnoses in Individuals with Substance

Use Disorders: A Phenome-Wide Survival Analysis

Peter B. Barr, PhD [a-d], Zoe E. Neale, PhD [a,b,d], Tim B. Bigdeli, PhD [a,b,d,e], Chris Chatzinakos, PhD [a,b],

Philip D. Harvey, PhD [f,g], Roseann E. Peterson, PhD [a,b], and Jacquelyn L. Meyers, PhD [a,b,e]

[a] SUNY Downstate Health Sciences University, Department of Psychiatry and Behavioral Sciences

[b] SUNY Downstate Health Sciences University, Institute for Genomics in Health

[c] SUNY Downstate Health Sciences University, Department of Community Health Sciences

[d] VA New York Harbor Healthcare System

[e] SUNY Downstate Health Sciences University, Department of Epidemiology and Biostatistics

[f] University of Miami Miller School of Medicine

[g] Research Service, Bruce W. Carter Miami Veterans Affairs (VA) Medical Center

Corresponding author: Peter B. Barr

450 Clarkson Ave, MSC 1203, Brooklyn, NY 11203

e-mail: peter.barr@downstate.edu.

Main text: 4,499 words

Abstract: 250 words

3 Tables; 3 Figures

ABSTRACT

Objective: Persons with substance use disorders (SUD) often suffer from additional comorbidities. Researchers have explored this overlap via phenome wide association studies (PheWAS). However, PheWAS are largely cross-sectional, limiting our understanding of whether diagnoses predate development of an SUD. We characterize whether polygenic scores (PGS) are associated with time to comorbid diagnoses in electronic health records (EHR) after the first documented SUD diagnosis.

Methods: Using data from All of Us (N = 393,596), we explored: 1) whether social determinants of health (SDoH) are associated with lifetime risk of SUD (N cases = 42,568) and 2) within a subset those with a diagnosed SUD and available genetic data SUD (N = 21,357), whether PGS for alcohol use disorders, cannabis use disorders, depression, externalizing, post-traumatic stress disorder, and schizophrenia were associated with subsequent diagnoses via a phenome-wide survival analysis.

Results: Multiple SDoH were associated with lifetime SUD diagnosis, with annual household income having the largest overall associations (e.g., <$10K annually vs $100K-$150K annually: OR = 4.18; 95% CI = 3.92, 4.45). There were 86 phenome-wide significant PGS associations with subsequent diagnoses across various bodily systems. PGSs for alcohol use disorders, post-traumatic stress disorder, and schizophrenia were each associated with time to their respective diagnoses.

Conclusions: Social determinants, especially those related to income, have profound associations with lifetime SUD risk. Additionally, PGS for psychiatric conditions are associated with multiple post-SUD diagnoses within those with a SUD, suggesting PGS may capture information beyond lifetime risk, including timing and severity of comorbidities related to SUD.

INTRODUCTION

Psychiatric disorders have far-reaching consequences for affected individuals, their families, the communities in which they live, and society more broadly (1–4). Substance use disorders (SUD) in particular are extremely detrimental. An estimated 107,000 Americans died as the result of an overdose in 2021 (5). In 2016, alcohol use contributed 4.2% to the global disease burden and other drug use contributed 1.3% (4). Excessive alcohol use and illicit drug use cost the United States an annual $250 billion (6) and $190 billion (7) respectively. Part of the increased mortality and morbidity in those with SUD occurs because if the increased number of co-occurring medical problems associated with having a SUD. Given the substantial human and economic costs of substance use disorders, understanding the ways SUD can contribute to risk for comorbidity has important public health implications.

The proliferation of large-scale biobanks – such as The Million Veteran Program (8), FinnGen (9), Biobank Japan (10), UK Biobank (11), and more recently, All of Us (12) – linking individual-level genomic data with electronic health records (EHRs) presents opportunities to further explore the relationships between SUD, or any contributory indicators (e.g., clinical diagnoses, polygenic scores), and a wide range of outcomes. This hypothesis-free approach, referred to as a phenome-wide association study (PheWAS) (13), can aid us in better understanding patterns of comorbidity with any given exposure. For example, recent PheWAS using polygenic scores (PGS) for schizophrenia, bipolar disorder, major depression, and broad externalizing risk (14–16) have identified widespread associations between PGSs and a host of psychiatric and other medical diagnoses spanning all bodily systems and have significant potential implications for public health strategies.

To date, PheWAS have primarily used cross-sectional data. This lifetime-only approach limits the potential to understand: 1) whether certain "exposures" occur after the onset of a given condition, obscuring the time-order of comorbid diagnoses, and 2) the degree to which diagnoses may lead to a cascade of other comorbidities. For example, using lifetime smoking as the exposure, we could potentially misinterpret comorbid psychiatric conditions as consequences of smoking in the case when they are a risk factor for smoking. Additionally, we may miss the consequences of heavy smoking, and

time to their onset, if we do not focus on smoking quantity and post-initiation diagnoses among

smokers. In the current study, we move beyond lifetime diagnosis in PheWAS to characterize whether

different PGS are associated with time to comorbid diagnoses in after the first indication of SUD in

EHRs. We do so by utilizing longitudinal EHR data from the All of Us Research Program, which is more

demographically representative than previous work in this area.

The clinical utility of PGSs is an ongoing area of debate (17–22). We add to this discussion in

three ways. First, we explore the potential use of polygenic scores *within individuals who are already*

diagnosed. We chose substance use disorders specifically because of the wide array of medical and

psychiatric consequences related to having a SUD. Second, we move beyond a focus of lifetime

associations in PheWAS to characterize whether polygenic scores are associated with subsequent

comorbid diagnoses appearing in the EHR *after the first recorded entry of substance use disorder*

(SUD). Exploring the post-SUD diagnosis association of polygenic scores (PGS) for psychiatric and

substance use disorders with subsequent medical diagnoses can help characterize the vast pleiotropic

impact of genetic risk for these conditions, which could reflect shared genetic effects (biological

pleiotropy, e.g., a common liability contributes to risk for both SUD and post-traumatic stress disorder,

or PTSD, explaining the comorbidity) or a potential causal chain of events (mediated pleiotropy, e.g.,

liability for AUD contributes to increased alcohol use, resulting in liver disease). Lastly, we harness the

diversity in All of Us to move beyond the limited focus on populations most similar to European

reference panels. Knowledge gained regarding the potential medical complications likely to arise in

individuals with SUD with and without genetic risk for SUD can lead to preventative actions or improved

screening that may reduce the onset of these additional comorbidities**.**

Using data from the All of Us Research Programs' EHR (Release 8, N = 393,596), we first

explored whether several social determinants of health were associated with lifetime risk of SUD, given

their importance in the onset of SUD (23).We did this, in part, to characterize patterns of diagnosis and

assess potential biases when selecting those with a SUD in EHR. Conditioning on those that have a

diagnosis increases the potential for collider bias in downstream analyses (24), as seen in recent

analyses of polygenic scores within those that have psychotic disorders (25). Next, harnessing the longitudinal quality of All of Us, we examined whether PGSs for six psychiatric and substance use disorders were associated with subsequent comorbidities post-SUD diagnosis, by performing a phenome-wide survival analysis. Our analyses inform the degree to which genetic and environmental risk factors are important in the course of SUD and related medical problems. While the PheWAS is exploratory in nature, we expect: 1) polygenic scores for a psychiatric conditions to be associated with subsequent diagnoses for their respective phenotype, and 2) these polygenic scores to be associated with subsequent comorbidities relevant for each condition (e.g., AUD PGS and liver conditions).

METHODS

The All of Us Research Program

All of Us is a prospective, nationwide cohort study aiming to study the effects of environment, lifestyle, and genomics on health outcomes. Participant recruitment is predominantly done through participating health care provider organizations and in partnership with Federally Qualified Health Centers. Interested participants can enroll as direct volunteers, visiting community-based enrollment sites. Enrollment, informed consent, and baseline health surveys are administered digitally through the All of Us program website (https://joinallofus.org). Participants are next invited to undergo a basic physical exam and biospecimen collection at an affiliated healthcare site. Participant follow-up occurs through both passive linkage with EHR and active periodic follow-up surveys. We included the full sample with EHR data for associations between social risk factors and lifetime SUD diagnosis (N = 393,596). For the genomic analyses, we included all participants who had electronic health record (EHR), had short-read whole genome sequence (WGS) data from release 8 (May 6, 2018 to October 1, 2023), and whose genetic similarity matched populations from available genome wide association studies (GWAS). Additionally, we excluded those with self-reported military service to remove potential overlap with the GWASs used to generate PGS, such as GWAS from the Million Veteran Program, leaving the final sample with a lifetime SUD and genomic data at $N = 21{,}357$.

Genotyping

In the current release of All of Us (release 8), N = 414,840 participants have available short-

read sequencing data. To ensure consistency across sites for DNA extraction and sequencing, AoU

developed a standardized process and QC metrics across sites. Sequencing was performed on the

Illumina NovaSeq 6000 instrument. A full description of the collection, harmonization, sequencing, and

population assignment pipeline has been published elsewhere (26). To correct for population structure

in the genetic data, participants were assigned to genetic similarity clusters of those most similar to

European (EUR-like) and African (AFR-like) participants in the 1000 Genomes and the Human Genome

Diversity Project (27–29). Genetic principal components (PCs) were generated in Hail (30).

Electronic health records (EHRs)

We used phecodes, which are validated clusters of ICD-9/10-CM codes in the EHR (31–34), to

create lifetime diagnoses for SUD (i.e., across the entire course of one's EHR) and the subsequent

outcomes for the PheWAS. We considered individuals as meeting criteria for an SUD if they had two or

more outpatient or one inpatient occurrence of phecodes 316 (Substance addiction and disorders,

tobacco-related disorders excluded) or 317 (Alcohol-related disorders) in their EHR. Prior analyses

have shown that 2 or more phecodes is a good predictor of diagnosis, and we chose this definition to

limit diagnostic bias (14, 15). The date of the first recorded SUD in participants EHR was used as the

index date for all longitudinal analyses. We focus on diagnoses of alcohol and drug-related disorders,

excluding those *only* diagnosed with tobacco use disorders. Alcohol and other drug use disorders have

substantial genetic overlap (35, 36) that overlaps relatively less with risk for tobacco related disorders

(37–39). We performed a series of sensitivity analyses including tobacco use disorders (phecode 318)

to examine whether the inclusion of tobacco use disorder changed the pattern of results. For PheWAS

outcomes, we used the presence of any phecode following the initial diagnosis of SUD. We excluded

phecodes that occurred at a rate lower than 1% in each population. Our choice to use a single phecode

following SUD was driven by: 1) the need to ensure adequate power given the smaller overall sample

size for SUD cases and relative infrequency of some EHR codes, and 2) many of the common

comorbidities (e.g. obesity, hypertension, type 2 diabetes) lack the level of diagnostic uncertainty

present in psychiatric diagnoses that more often require a higher threshold for certainty.

Social and demographic risk factors

We included a variety of social and demographic measures available from the baseline survey.

For the current analysis we included age, gender (man, woman, or trans and gender nonconforming),

self-reported race-ethnicity (Asian American/Pacific Islander, Black/African-American, Hispanic or

Latino/a/x, Multi-racial, Non-Hispanic White, and other race-ethnicity), education (less than high school,

HS diploma or GED, some college, college graduate, and advanced degree), household income (less

than $10k to more than $200), marital status (never married, married, cohabitating, divorced,

separated, and widowed), health insurance (insured vs uninsured), and place of birth (US born vs

foreign born). Our reference categories (married, Non-Hispanic White, college graduate, etc.) were

selected because they reflect those that are typically most socially advantaged and have better health,

on average. We focused on the association between these social risk factors and lifetime SUD

diagnosis, only. Because these items are measured at baseline entry into All of Us and not necessarily

time of SUD diagnoses, we lack the ability to establish whether potentially time-variant measures were

the same before their first SUD diagnosis.

Polygenic scores (PGS)

We estimated PGSs, which are aggregate measures of the number of risk alleles individuals

carry weighted by effect sizes from GWAS summary statistics, from multiple large-scale GWASs for

alcohol use disorders/problematic alcohol use, cannabis use disorders, broad externalizing risk,

depression, post-traumatic stress disorder, and schizophrenia (40–46). We included these specific

PGSs because: 1) there is strong genetic overlap between psychiatric conditions disorders, 2) these

PGS cover a range of risk for internalizing, externalizing, and thought disorders (40–42, 44, 47, 48),

and 3) each of these GWAS included results for AFR-like participants, allowing us to move beyond

EUR-like only analyses. We created PGSs using PRS-CSx (49), a Bayesian regression and continuous

shrinkage method that estimates the posterior effect sizes for each SNP in a given set of GWAS

summary statistics. PGS accuracy decays continuously as target samples differ in ancestral

background from the discovery GWAS, even within relatively homogenous genetic clusters (50). PRS-

CSx uses multiple populations to improve power of PGS in underpowered samples, typically those who

are not in the EUR-like grouping. For PRS-CSx, we used the *auto* flag to identify the optimal shrinkage

parameter (phi), the *meta* flag to generate the weighted effect sizes estimates, and the default settings

for all other flags. We standardized all PGSs to Z-scores for interpretation.

We note that our paper includes language related to both race-ethnicity, which reflects socially-

constructed categories, and genetic similarity, which uses empirical assignment based on available

reference panels, because both are relevant for the current analyses. Prior work has established race-

ethnicity (and with it, racism and discrimination) are relevant for disparities in SUDs (51–55). Informed

by best practices for handling genetic data from diverse populations (56), we stratified analyses by

genetic similarity and included genetic principal components, which limit the possibility of false positives

due to population stratification. Race-ethnicity was used in the analyses related to sociodemographic

risk factors while genetic similarity was used in PGS analyses. The inclusion of both concepts is in no

way endorsing the notion that these reflect discrete biological categories.

Electronic Health Record (EHR) specific covariates

We included several covariates specific for EHR-based analyses. First we construct measures

for length of EHR (time from first to most recent documented code) and healthcare utilization (total

count of documented billing codes across the EHR record) using the *PheTK* package, specifically

designed for work in All of Us (57). To account for comorbidities that predated SUD diagnosis, we

created comorbidity burden score by taking the inverse normal transformation of the total count of

unique phecodes individuals had in their EHR prior to SUD, used in previous PheWAS analyses (15,

16).

Analytic plan

Figure 1 demonstrates how the analytic samples for each of the analyses were selected. First,

we examined the association between social and demographic measures and lifetime SUD diagnosis

using logistic regression (N = 393,596). Next, we expanded on the traditional PheWAS approach by

performing a phenome wide survival analysis (N = 21,357). We utilized Cox proportional hazards

models to estimate the association (in the form of hazard ratios, or HR) between the index date (time of

initial SUD diagnosis in EHR) to first documented diagnosis for each phecode, as PheWAS is a

hypothesis-free approach which examines *all* outcomes instead of just theoretically relevant ones. The

bottom panel in Figure 1 provides a visual depiction of how the timelines might vary for respondents in

the survival models. In the PGS models, we included all 6 PGS simultaneously. We stratified by genetic

similarity grouping (AFR-like and EUR-like) and included age at SUD diagnosis, gender, the first 10

genetic principal components, pre-SUD diagnosis comorbidity burden, length of EHR, and healthcare

utilization as covariates. We did not impose any predefined exclusionary criteria regarding length of

EHR record since we used the date of first SUD record as index date and the Cox proportional hazards

model is well-suited to handle right censored data. We performed all survival models using the *survival*

package (version 3.7.0) in R (version 4.4.1). Finally, we meta-analyzed results across genetic-similarity

via fixed-effects meta-analysis in the *meta* package (version 7.0.0) in R. To correct for multiple testing,

we applied a false discovery rate (FDR) of 5% (58).

RESULTS

Defining persons with lifetime SUD in EHR

Using the 2+ outpatient/1+ inpatient definition of substance use disorder diagnosis, we identified

N = 42,568 individuals who met our criteria for SUD in the full data with EHR available. Table 2

presents demographic characteristics for the full sample with available EHR data and those who met

our criteria for SUD. This demographic breakdown of the SUD sample largely reflects the patterns seen

in nationally representative samples (51, 52).

Social and Demographic results

Figure 2 presents the bivariate and adjusted (multivariable) results from the logistic regression

models examining the association between social and demographic risk factors and SUD diagnosis in

the full sample with available EHR data for two selected SDoH: annual household income and marital

status (N = 393,596). These results largely mimicked prior analyses in earlier versions of the All of Us

data (59), presented here as odds ratios (OR) and corresponding 95% confidence intervals (CI). There

was a stark gradient in lifetime SUD diagnosis across income, whereby those with the lowest income

had the greatest odds of lifetime diagnosis (adjusted OR = 4.18; CI = 3.92, 4.45) relative to those

reporting annual incomes of \$100K - \$150K. Additionally those that were separated (adjusted OR =

2.32; CI = 2.20, 2.45) or divorced (adjusted OR = 1.97; CI = 1.91, 2.05) had significantly higher odds of

SUD diagnosis relative to those that were married. Results were slightly attenuated when moving from

the bivariate to adjusted (inclusion of all social risk factors and covariates simultaneously), but the

patterns remained unchanged. The full results are available in Supplemental Tables 1 & 2.

Polygenic Score (PGS) Survival PheWAS

Moving to those with an SUD diagnosis only, we further constrained to those of AFR-like and

EUR-like genetic similarity for subsequent within-SUD survival models using PGSs (Combined N =

21,357, see Supplemental Table S3 for stratified results). The subset of EUR-like and AFR-like

participants did not differ significantly in age from the full SUD sample (mean age = 50.45, SD = 14.24),

but there was a significantly higher proportion of women compared to the broader SUD sample

(51.22%, χ^2 = 167.33, df = 1, p = 2.83x10^{-38}). The vast majority identified as Non-Hispanic White or

Black/African American (86.93%). In total, we examined the associations with 846 phecodes following

initial SUD diagnosis after filtering those that did not occur in 1% or more of either population (full list of

phecodes in Supplemental Table S4). After adjusting for multiple testing, only 86 (10.1%) of the

associations remained significant. The proportion that had a given code prior to SUD diagnosis ranged

from 0.17% (phecode 797.1, cardiogenic shock) to 31.25% (phecode 745.0, pain in joint, full results

Supplemental Table S4), showing that many of these post-SUD codes reflect new incident cases. A

selection of the top associations for each PGS are presented in Table 3 (see Supplemental Table S4

for full results). Of all the PGSs, the PGS for schizophrenia (SCZ) showed the greatest number of trait

associations, followed by the PGSs for PTSD, externalizing (EXT), and depression (DEP). The PGSs

for alcohol use disorder (AUD) and cannabis use disorder (CUD) were each only associated with one

future phecode. Importantly, PGSs for SCZ, PTSD, and AUD were associated with time to SCZ (HR =

1.21; 95% CI = 1.15, 1.27), PTSD (HR = 1.13; 95% CI = 1.08, 1.19), and AUD (HR = 1.08; 95% CI =

1.05, 1.11), respectively.

PGSs were associated with multiple post-SUD-diagnosis comorbidities. For the SCZ PGS, the

strongest associations were with SCZ-related diagnoses, including psychosis (HR = 1.21; 95% CI =

1.14, 1.28) and paranoid disorders (HR = 1.30; 95% CI = 1.20, 1.40). For PTSD the strongest

associations were epilepsy (HR = 1.25; 95% CI = 1.12, 1.29) and cardiovascular conditions (angina

pectoris: HR = 1.13; 95% CI = 1.05, 1.21). The EXT PGS was primarily related to potential

consequences of substance use, such as smoking (emphysema: HR = 1.16, 95% CI = 1.10, 1.22;

dependence on respirator or supplemental oxygen: HR = 1.13, 95% CI = 1.05, 1.21) or intravenous

drug use (viral hepatitis C: HR = 1.15, 95% CI = 1.10, 1.20). The DEP PGS was primarily associated

with subsequent psychiatric diagnoses (parasomnia: HR = 1.26, 95% CI = 1.11, 1.43;

antisocial/borderline personality disorder: HR = 1.15, 95% CI = 1.07, 1.24). Lastly, the CUD PGS was

only associated with subsequent viral hepatitis C infection (HR = 1.10, 95% CI = 1.05, 1.15).

Figure 3 presents two of the top associations between the PTSD and EXT PGSs and time to

subsequent: 1) psychosis and 2) viral hepatitis C codes, respectively. Here PGSs were stratified by

standard deviations (SD), ranging from -2 SD (red) to +2 SD (purple). While the overall effect of the

PGSs was small, by the end of observation, the difference in probability of "survival" between these two

extremes was approximately 12% lower for psychosis and 10% lower for viral hepatitis C in the +2 SD

group. This sizeable difference reiterates how small effects can still have considerable effects when

viewed over a longer time scale.

Lastly, we repeated all of the previous analyses while including those with that only met criteria

for tobacco use disorder (phecode 318) as part of our definitions of SUD diagnosis. This wider definition

captured significantly more people (N = 67,729) and included 900 phecodes which occurred at 1% or

more in the analytic sample. While there were additional significant associations within the survival

PheWAS (162 phenome-wide significant associations, 18.11% of outcomes tested), the pattern of

results largely mimicked those from the more restricted definitions in both sets of analyses. All of the

results from the more expansive SUD definition are presented in the supplemental information

(Supplemental Tables 5 – 8).

DISCUSSION

Large-scale biobanks and genetic data are becoming increasingly prevalent in health research,

offering the potential to explore multiple comorbidities simultaneously. The goal of precision medicine is

harnessing these sources of information to personalize treatment and stratify risk. However, much of

the work to date has focused on lifetime risk for a single diagnosis. In the current analyses, we expand

upon existing research by focusing on risk longitudinally and within persons who have a SUD diagnosis

to begin to understand what value risk factors might play in helping those who already have a

diagnosis.

In terms of lifetime risk for SUD, we found multiple social and demographic factors associated

with lifetime SUD diagnosis. These results largely mimic prior findings in All of Us (59) and in the

population more broadly (51, 52), whereby those who largely occupy marginalized positions are at

greater risk for having a SUD. The most striking finding is the gradient in income, whereby those

reporting an annual household income less than $10k annually had ~4 times the odds of SUD-

diagnosis relative to those reporting annual incomes of $100k - $150k annually, reflecting either social

determinants as major risk factors or the disabling impact of SUD on social mobility. The increased rate

of diagnosis among those who identify as Black or African-American compared to Non-Hispanic Whites

disappeared after accounting for other social determinants of health, suggesting the increased rates of

diagnoses in this population may reflect socioeconomic inequalities and the role of systemic racism in
limiting access to economic resources.

Focusing on genetic risk within persons who had a SUD diagnosis, 86 associations between
PGS and subsequent phecodes remained significant after correcting for multiple testing (~10% of
outcomes tested), including associations between PGSs for SCZ, PTSD, and AUD and time to their
corresponding diagnoses. These results increase confidence that associations are not merely spurious,
as these PGSs demonstrated specificity for the expected outcomes. Additionally, these associations
inform the degree to which PGS for psychiatric conditions may be relevant in those who already have a
diagnosis for another psychiatric or substance use disorder. For example, PGS for both PTSD and SCZ
were relevant for time to subsequent PTSD and schizophrenia diagnoses, respectively. Given the
relatively strong genetic overlap between both PTSD and schizophrenia with SUDs (42, 48, 60), the
continued relevance of these PGS within SUD cases demonstrates that having a diagnosis for a
specific outcome (e.g. SUD) may not be sufficient to account for the genetic overlap between that trait
and other diagnoses (e.g. PTSD or SCZ). Lastly, the association between the AUD PGS and
subsequent AUD codes suggests that PGS not only capture lifetime risk for a diagnosis, but they may
also capture aspects disease of severity, given the association with a repeated EHR codes, occurring
earlier in those already diagnosed with SUD.

The survival PheWAS results also highlighted risk of comorbid conditions that occur after SUD
diagnosis. A PGS for externalizing was associated with a variety of smoking-related conditions (e.g.,
chronic airway obstruction, use of a ventilator, etc.) as well as other potential consequences of SUD
(e.g. viral hepatitis C). Prior work on externalizing PGS in both the Million Veteran Program and the
Vanderbilt University Biobank revealed many of the same top associations (16, 34), helping add to the
confidence in these associations. PGS for PTSD and depression were both associated with a variety of
physical comorbidities, especially those related to cardiovascular disease and its risk factors. These
associations are in line with broader epidemiological evidence which finds both depression and PTSD
as consistent risk factors for the development of cardiovascular disease (61–63). SCZ PGS were most

strongly associated with schizophrenia-related codes, including codes for paranoid disorders and

psychosis, again consistent with other PheWAS of SCZ PGS (14, 15). Importantly, the SCZ PGS had

the most significant associations, suggesting that while it is highly specific to schizophrenia risk, it

captures other comorbidities when a diagnosis is not always available. Lastly, each of the polygenic

scores were also associated with a *longer* time to a variety of diagnoses in the EHR. While this could

be interpreted as some type of protective effect, the more likely explanation is those at greater risk are

less likely to treatment (64, 65), especially as barriers to access, such as health insurance and

economic resources, were key predictors in the social demographic correlates.

When we consider the results from the SDoH and PGS analyses together, we can see how the

strong gradients across social conditions may be particularly relevant for considering *who* we are

studying in EHR-based analyses of diagnosed cases. First, conditioning on a potential collider, such as

SUD diagnosis, can bias downstream associations between PGS and outcomes in unpredictable ways

(25, 66), so results should be interpreted with this potential bias in mind. Second, SDoH are clearly

relevant for lifetime SUD risk and most likely important for associated comorbidities. Socioeconomic

conditions may confound relationships between PGS and outcomes, since polygenic scores are

confounded, at least in part, by environmental variance (67). While we cannot determine the degree to

which socioeconomic may: 1) confound or 2) moderate the relationship between PGS and subsequent

diagnoses, future analyses in All of Us that focus prospectively from time of enrollment can potentially

better answer these questions.

This work has several important limitations. First, we lacked the social and demographic risk

factors measured at time of diagnosis and could not establish the time ordering between these

measures. As All of Us grows through recruitment, data generation, and passive data collection via

constantly updating EHRs, we will be able to explore the prospective associations between important

social determinants of health and diagnoses. Second, the use of EHR data, while convenient, is also

confounded by access and healthcare utilization. We cannot discern whether associations are truly

reflective of the progression in disease processes or whether they reflect propensity for help seeking

when available in a healthcare setting. Third, this analysis focused on diagnoses that occurred after a

recorded SUD. We did not address the scenario in which SUD codes follow other diagnoses (especially

psychiatric diagnoses). However the framework we employed here could easily be extended to those

other scenarios. Lastly, though we have attempted to be more inclusive in the genetic analyses, we still

lacked sufficient GWAS summary statistics for other genetic similarity groups to include here. As a field,

we must continue to strive to ensure results from genetic discoveries can be applied to all populations,

equitably (56).

Harnessing the longitudinal data in the All of Us database, we have demonstrated the

importance of various social conditions for the lifetime diagnosis of substance use disorders. Annual

income is especially relevant in disparities of SUD. Additionally, we have also shown that in persons

who have a SUD diagnosis, various measures of genetic risk were associated with time to subsequent

diagnoses in their EHR, moving beyond typical cross-sectional approaches. While there is considerable

work to be done for the use of social, clinical, and biological data within a healthcare setting, the current

results demonstrate the potential of these approaches. Future work should endeavor to integrate

across levels of analysis in a longitudinal framework.

ACKNOWLEDGEMENTS

This study was supported in part by National Institute of Mental Health (R01MH125938: Drs Peterson, Bigdeli, Chatzinakos, and Meyers); the National Institute of Drug Abuse (R01DA050721: Dr Barr; R01DA060596: Drs Meyers, Barr, Chatzinakos, and Neale), and the National Institute on Alcohol Abuse and Alcoholism (R01AA030010: Drs Meyers, Barr, Chatzinakos, and Neale). Computing costs associated with this work was supported by R01MH125938 (PI: Peterson). The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The All of Us Research Program is supported by the National Institutes of Health, Office of the Director: Regional Medical Centers: 1 OT2 OD026549; 1 OT2 OD026554; 1 OT2 OD026557; 1 OT2 OD026556; 1 OT2 OD026550; 1 OT2 OD 026552; 1 OT2 OD026553; 1 OT2 OD026548; 1 OT2 OD026551; 1 OT2 OD026555; IAA #: AOD 16037; Federally Qualified Health Centers: HHSN 263201600085U; Data and Research Center: 5 U2C OD023196; Biobank: 1 U24 OD023121; The Participant Center: U24 OD023176; Participant Technology Systems Center: 1 U24 OD023163; Communications and Engagement: 3 OT2 OD023205; 3 OT2 OD023206; and Community Partners: 1 OT2 OD025277; 3 OT2 OD025315; 1 OT2 OD025337; 1 OT2 OD025276. In addition, the All of Us Research Program would not be possible without the partnership of its participants. We are grateful to Tadeusz H Wroblewski for sharing the image for survival models in All of Us.

CONFLICTS OF INTEREST

Dr. Harvey reported receiving personal fees from Boehringer Ingelheim, Bioexcel, Karuna Therapeutics, Minerva Neuroscience, Alkermes, Sunovion, and Roche; royalties from WCG Endpoint Solutions; and equity from i-Function outside the submitted work. The remaining authors had no relationships with financial interests.

REFERENCES

1.   Ferrari A: Global, regional, and national burden of 12 mental disorders in 204 countries and

territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019

[Internet]. Lancet Psychiatry 2022; 9:137–150[cited 2022 Feb 17] Available from:

http://www.thelancet.com/article/S2215036621003953/fulltext

2.   Murray CJL, Mokdad AH, Ballestros K, et al.: The state of US health, 1990-2016: Burden of

diseases, injuries, and risk factors among US states [Internet]. JAMA - Journal of the American

Medical Association 2018; 319:1444–1472[cited 2022 Jan 12] Available from:

https://jamanetwork.com/journals/jama/fullarticle/2678018

3.   Reitsma MB, Fullman N, Ng M, et al.: Smoking prevalence and attributable disease burden in

195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of

Disease Study 2015 [Internet]. The Lancet 2017; 389:1885–1906Available from:

http://www.sciencedirect.com/science/article/pii/S014067361730819X

4.   Degenhardt L, Charlson F, Ferrari A, et al.: The global burden of disease attributable to alcohol

and drug use in 195 countries and territories, 1990–2016: a systematic analysis for the Global

Burden of Disease Study 2016 [Internet]. Lancet Psychiatry 2018; 5:987–1012Available from:

https://doi.org/10.1016/S2215-0366(18)30337-7

5.   U.S. Overdose Deaths In 2021 Increased Half as Much as in 2020 - But Are Still Up 15%

[Internet][cited 2022 May 15] Available from:

https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/202205.htm

6.   Sacks JJ, Gonzales KR, Bouchery EE, et al.: 2010 National and State Costs of Excessive

Alcohol Consumption. Am J Prev Med 2015; 49:e73–e79

7.   National Drug Intelligence Center: National drug threat assessment. Washington, DC, United

States Department of Justice, 2011

8.   Gaziano JM, Concato J, Brophy M, et al.: Million Veteran Program: A mega-biobank to study

genetic influences on health and disease. J Clin Epidemiol 2016; 70:214–223[cited 2021 Oct 26]

9. Kurki MI, Karjalainen J, Palta P, et al.: FinnGen provides genetic insights from a well-phenotyped

isolated population [Internet]. Nature 2023; 613:508–518[cited 2023 Feb 21] Available from:

https://www.nature.com/articles/s41586-022-05473-8

10. Nagai A, Hirata M, Kamatani Y, et al.: Overview of the BioBank Japan Project: Study design and

profile [Internet]. J Epidemiol 2017; 27:S2–S8[cited 2021 Oct 26] Available from:

http://dx.doi.org/10.1016/j.je.2016.12.0050917-5040/

11. Bycroft C, Freeman C, Petkova D, et al.: The UK Biobank resource with deep phenotyping and

genomic data [Internet]. Nature 2018; 562:203–209[cited 2021 Oct 26] Available from:

https://www.nature.com/articles/s41586-018-0579-z

12. The All of Us Research Program Investigators: The "All of Us" Research Program [Internet]. New

England Journal of Medicine 2019; 381:668–676[cited 2021 Oct 26] Available from:

https://www.nejm.org/doi/full/10.1056/NEJMsr1809937

13. Denny JC, Ritchie MD, Basford MA, et al.: PheWAS: Demonstrating the feasibility of a phenome-

wide scan to discover gene-disease associations [Internet]. Bioinformatics 2010; 26:1205–

1210[cited 2022 Mar 28] Available from: https://pubmed.ncbi.nlm.nih.gov/20335276/

14. Zheutlin AB, Dennis J, Linnér RK, et al.: Penetrance and pleiotropy of polygenic risk scores for

schizophrenia in 106,160 patients across four health care systems [Internet]. American Journal

of Psychiatry 2019; 176:846–855[cited 2022 Jan 5] Available from:

https://pubmed.ncbi.nlm.nih.gov/31416338/

15. Bigdeli TB, Voloudakis G, Barr PB, et al.: Penetrance and Pleiotropy of Polygenic Risk Scores

for Schizophrenia, Bipolar Disorder, and Depression among Adults in the US Veterans Affairs

Health Care System [Internet]. JAMA Psychiatry 2022; 79:1092–1101[cited 2023 Jan 23]

Available from: https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2796413

16. Barr PB, Bigdeli TB, Meyers JL, et al.: Correlates of Risk for Disinhibited Behaviors in the Million

Veteran Program Cohort [Internet]. JAMA Psychiatry 2024; 81:188–197Available from:

https://doi.org/10.1001/jamapsychiatry.2023.4141

17.   Lewis CM, Vassos E: Polygenic risk scores: From research tools to clinical instruments [Internet].

Genome Med 2020; 12:1–11[cited 2022 Aug 1] Available from:

https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-020-00742-5

18.   Martin AR, Kanai M, Kamatani Y, et al.: Clinical use of current polygenic risk scores may

exacerbate health disparities [Internet]. Nat Genet 2019; 51:584–591Available from:

https://doi.org/10.1038/s41588-019-0379-x

19.   Wray NR, Lin T, Austin J, et al.: From Basic Science to Clinical Application of Polygenic Risk

Scores: A Primer [Internet]. JAMA Psychiatry 2021; 78:101–109[cited 2022 Aug 1] Available

from: https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2771079

20.   Torkamani A, Wineinger NE, Topol EJ: The personal and clinical utility of polygenic risk scores

[Internet]. Nat Rev Genet 2018; 19:581–590Available from: https://doi.org/10.1038/s41576-018-

0018-x

21.   Murray GK, Lin T, Austin J, et al.: Could Polygenic Risk Scores Be Useful in Psychiatry?: A

Review [Internet]. JAMA Psychiatry 2021; 78:210–219Available from:

https://doi.org/10.1001/jamapsychiatry.2020.3042

22.   Klarin D, Natarajan P: Clinical utility of polygenic risk scores for coronary artery disease

[Internet]. Nat Rev Cardiol 2022; 19:291–301Available from: https://doi.org/10.1038/s41569-021-

00638-w

23.   Barr PB, Driver MN, Kuo SIC, et al.: Clinical, environmental, and genetic risk factors for

substance use disorders: characterizing combined effects across multiple cohorts [Internet]. Mol

Psychiatry 2022; 27:4633–4641[cited 2022 Aug 24] Available from:

https://www.medrxiv.org/content/10.1101/2022.01.27.22269750v3

24.   Tattan-Birch H, Marsden J, West R, et al.: Assessing and addressing collider bias in addiction

research: the curious case of smoking and COVID-19 [Internet]. Addiction 2021; 116:982–

984Available from: https://doi.org/10.1111/add.15348

25.   Asim A, Yang Y, Adorjan K, et al.: The impact of collider bias on genetic prediction in psychotic

463   disorders [Internet]. Neuropsychopharmacology 2026; 51:430–439Available from:

464   https://doi.org/10.1038/s41386-025-02285-y

465   26.   Bick AG, Metcalf GA, Mayo KR, et al.: Genomic data in the All of Us Research Program

466   [Internet]. Nature 2024; 627:340–346Available from: https://doi.org/10.1038/s41586-023-06957-x

467   27.   National Academies of Sciences and Medicine E: Using population descriptors in genetics and

468   genomics research: A new framework for an evolving field [Internet]. Washington, DC, The

469   National Academies Press, 2023Available from:

470   https://nap.nationalacademies.org/catalog/26902/using-population-descriptors-in-genetics-and-

471   genomics-research-a-new

472   28.   Cavalli-Sforza LL: The Human Genome Diversity Project: past, present and future [Internet]. Nat

473   Rev Genet 2005; 6:333–340Available from: https://doi.org/10.1038/nrg1596

474   29.   Auton A, Abecasis GR, Altshuler DM, et al.: A global reference for human genetic variation

475   [Internet]. Nature 2015; 526:68–74Available from: http://dx.doi.org/10.1038/nature15393

476   30.   Hail Team: Hail 0.2. [Internet][cited 2024 Dec 10] Available from: https://github.com/hail-is/hail

477   31.   Denny JC, Bastarache L, Ritchie MD, et al.: Systematic comparison of phenome-wide

478   association study of electronic medical record data and genome-wide association study data

479   [Internet]. Nat Biotechnol 2013; 31:1102–1110[cited 2021 Nov 9] Available from:

480   https://www.nature.com/articles/nbt.2749

481   32.   Wu P, Gifford A, Meng X, et al.: Mapping ICD-10 and ICD-10-CM codes to phecodes: Workflow

482   development and initial evaluation. J Med Internet Res 2019; 21:1–13

483   33.   Wei WQ, Teixeira PL, Mo H, et al.: Combining billing codes, clinical notes, and medications from

484   electronic health records provides superior phenotyping performance [Internet]. Journal of the

485   American Medical Informatics Association 2016; 23:20–27[cited 2022 Jan 11] Available from:

486   https://pubmed.ncbi.nlm.nih.gov/26338219/

487   34.   Wei W-Q, Bastarache LA, Carroll RJ, et al.: Evaluating phecodes, clinical classification software,

488   and ICD-9-CM codes for phenome-wide association studies in the electronic health record. PLoS

489   One 2017; 12:e0175508

490   35.   Barr PB, Dick DM: The Genetics of Externalizing Problems [Internet]. Curr Top Behav Neurosci

491   2020;   47:93–112[cited   2021   Jul   25]   Available   from:

492   https://link.springer.com/chapter/10.1007/7854_2019_120

493   36.   Karlsson Linnér R, Mallard TT, Barr PB, et al.: Multivariate analysis of 1.5 million people

494   identifies genetic associations with traits related to self-regulation and addiction [Internet]. Nat

495   Neurosci 2021; 1–10Available from: https://www.nature.com/articles/s41593-021-00908-3

496   37.   Kendler KS, Myers J: The boundaries of the internalizing and externalizing genetic spectra in

497   men   and   women   [Internet].   Psychol   Med   2014;   44:647–655Available   from:

498   https://www.cambridge.org/core/article/boundaries-of-the-internalizing-and-externalizing-genetic-

499   spectra-in-men-and-women/BF8E3BE0A5FACFC1FB3C66EDCD18EF13

500   38.   Khan Y, Davis CN, Jinwala Z, et al.: Transdiagnostic and Disorder-Level Genome-Wide

501   Association Studies Enhance Precision of Substance Use and Psychiatric Genetic Risk Profiles

502   in African and European Ancestries [Internet]. Biol Psychiatry 2026; 99:68–79Available from:

503   https://doi.org/10.1016/j.biopsych.2025.04.021

504   39.   Hatoum AS, Johnson EC, Colbert SMC, et al.: The addiction risk factor: A unitary genetic

505   vulnerability characterizes substance use disorders and their associations with common

506   correlates [Internet]. Neuropsychopharmacology 2022; 47:1739–1745[cited 2022 Feb 16]

507   Available from: https://www.nature.com/articles/s41386-021-01209-w

508   40.   Levey DF, Stein MB, Wendt FR, et al.: Bi-ancestral depression GWAS in the Million Veteran

509   Program and meta-analysis in >1.2 million individuals highlight new therapeutic directions

510   [Internet].   Nat   Neurosci   2021;   [cited   2021   Jun   17]   Available   from:

511   http://www.nature.com/articles/s41593-021-00860-2

41.   Levey DF, Galimberti M, Deak JD, et al.: Multi-ancestry genome-wide association study of

cannabis use disorder yields insight into disease biology and public health implications [Internet].

Nat Genet 2023; 55:2094–2103Available from: https://doi.org/10.1038/s41588-023-01563-z

42.   Nievergelt CM, Maihofer AX, Atkinson EG, et al.: Genome-wide association analyses identify 95

risk loci and provide insights into the neurobiology of post-traumatic stress disorder [Internet].

Nat Genet 2024; 56:792–808Available from: https://doi.org/10.1038/s41588-024-01707-9

43.   Kranzler HR, Zhou H, Kember RL, et al.: Genome-wide association study of alcohol consumption

and use disorder in 274,424 individuals from multiple populations [Internet]. Nat Commun 2019;

10:1499Available from: https://www.ncbi.nlm.nih.gov/pubmed/30940813

44.   Zhou H, Kember RL, Deak JD, et al.: Multi-ancestry study of the genetics of problematic alcohol

use in over 1 million individuals [Internet]. Nat Med 2023; 29:3184–3192Available from:

https://doi.org/10.1038/s41591-023-02653-5

45.   Barr PB, Stephenson M, Poore HE, et al.: A Multivariate Genomic Investigation of the

Externalizing Spectrum and Suicide Risk [Internet]. medRxiv 2025;

2025.08.19.25332327Available from:

http://medrxiv.org/content/early/2025/08/24/2025.08.19.25332327.abstract

46.   Bigdeli TB, Chatzinakos C, Bendl J, et al.: Biological Insights from Schizophrenia-associated

Loci in Ancestral Populations [Internet]. medRxiv 2024; 2024.08.27.24312631Available from:

http://medrxiv.org/content/early/2024/08/28/2024.08.27.24312631.abstract

47.   Deak JD, Zhou H, Galimberti M, et al.: Genome-wide association study in individuals of

European and African ancestry and multi-trait analysis of opioid use disorder identifies 19

independent genome-wide significant risk loci [Internet]. Mol Psychiatry 2022; 27:3970–

3979Available from: https://doi.org/10.1038/s41380-022-01709-1

48.   Trubetskoy V, Pardiñas AF, Qi T, et al.: Mapping genomic loci implicates genes and synaptic

biology in schizophrenia [Internet]. Nature 2022; 604:502–508[cited 2022 Apr 10] Available from:

https://www.nature.com/articles/s41586-022-04434-5

49.   Ruan Y, Lin YF, Feng YCA, et al.: Improving polygenic prediction in ancestrally diverse

populations [Internet]. Nat Genet 2022; 54:573–580Available from:

https://doi.org/10.1038/s41588-022-01054-7

50.   Ding Y, Hou K, Xu Z, et al.: Polygenic scoring accuracy varies across the genetic ancestry

continuum [Internet]. Nature 2023; 618:774–781[cited 2023 May 16] Available from:

https://www.nature.com/articles/s41586-023-06079-4

51.   Grant BF, Goldstein RB, Saha TD, et al.: Epidemiology of DSM-5 alcohol use disorder results

from the national epidemiologic survey on alcohol and related conditions III [Internet]. JAMA

Psychiatry 2015; 72:757–766Available from: https://doi.org/10.1001/jamapsychiatry.2015.0584

52.   Grant BF, Saha TD, June Ruan W, et al.: Epidemiology of DSM-5 drug use disorder results from

the national epidemiologic survey on alcohol and related conditions-III [Internet]. JAMA

Psychiatry 2016; 73:39–47Available from: https://doi.org/10.1001/jamapsychiatry.2015.2132

53.   Williams DR: Race, Socioeconomic Status, and Health The Added Effects of Racism and

Discrimination [Internet]. Ann N Y Acad Sci 1999; 896:173–188Available from:

https://doi.org/10.1111/j.1749-6632.1999.tb08114.x

54.   Williams DR, Collins C: Racial residential segregation: a fundamental cause of racial disparities

in health [Internet]. Public Health Rep 2001; 116:404–416Available from:

http://www.ncbi.nlm.nih.gov/pubmed/12042604

55.   Williams DR, Mohammed SA: Discrimination and racial disparities in health: evidence and

needed research [Internet]. J Behav Med 2009; 32:20–47Available from:

http://www.ncbi.nlm.nih.gov/pubmed/19030981

56.   Peterson RE, Kuchenbaecker K, Walters RK, et al.: Genome-wide Association Studies in

Ancestrally Diverse Populations: Opportunities, Methods, Pitfalls, and Recommendations

[Internet]. Cell 2019; 179:589–603Available from: https://doi.org/10.1016/j.cell.2019.08.051

57.   Tran TC, Schlueter DJ, Zeng C, et al.: PheWAS analysis on large-scale biobank data with
PheTK [Internet]. Bioinformatics 2025; 41:btae719Available from:
https://doi.org/10.1093/bioinformatics/btae719

58.   Benjamini Y, Hochberg Y: Controlling the False Discovery Rate: A Practical and Powerful
Approach to Multiple Testing [Internet]. Journal of the Royal Statistical Society Series B
(Methodological) 1995; 57:289–300Available from: http://www.jstor.org/stable/2346101

59.   Barr PB, Bigdeli TB, Meyers JL: Prevalence, Comorbidity, and Sociodemographic Correlates of
Psychiatric Diagnoses Reported in the All of Us Research Program [Internet]. JAMA Psychiatry
2022; 79:622–628[cited 2022 Jun 20] Available from:
https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2791252

60.   Barr PB, Bountress K, Chatzinakos C, et al.: Multivariate genome-wide association study
(GWAS) of PTSD, Alcohol Use and Alcohol Use Disorders [Internet]. medRxiv 2025;
2025.03.24.25324454Available from:
http://medrxiv.org/content/early/2025/03/25/2025.03.24.25324454.abstract

61.   Padhi BK, Khatib MN, Serhan HA, et al.: Cardiovascular impact of post-traumatic stress disorder:
A systematic review and meta-analysis [Internet]. Curr Probl Cardiol 2024; 49:102632Available
from: https://www.sciencedirect.com/science/article/pii/S0146280624002718

62.   Edmondson D, Kronish IM, Shaffer JA, et al.: Posttraumatic stress disorder and risk for coronary
heart disease: A meta-analytic review [Internet]. Am Heart J 2013; 166:806–814Available from:
https://www.sciencedirect.com/science/article/pii/S0002870313005334

63.   Van der Kooy K, van Hout H, Marwijk H, et al.: Depression and the risk for cardiovascular
diseases: systematic review and meta analysis [Internet]. Int J Geriatr Psychiatry 2007; 22:613–
626Available from: https://doi.org/10.1002/gps.1723

64.   Mojtabai R, Evans-Lacko S, Schomerus G, et al.: Attitudes Toward Mental Health Help Seeking
as Predictors of Future Help-Seeking Behavior and Use of Mental Health Treatments
[Internet]2016; 67:650–657Available from: https://doi.org/10.1176/appi.ps.201500164

65.   Blanco C, Iza M, Rodríguez-Fernández JM, et al.: Probability and predictors of treatment-seeking

589   for substance use disorders in the U.S [Internet]. Drug Alcohol Depend 2015; 149:136–

590   144Available from: https://www.sciencedirect.com/science/article/pii/S0376871615000514

591   66.   Akimova ET, Breen R, Brazel DM, et al.: Gene-environment dependencies lead to collider bias in

592   models with polygenic scores [Internet]. Sci Rep 2021; 11:1–9[cited 2022 Dec 6] Available from:

593   https://www.nature.com/articles/s41598-021-89020-x

594   67.   Young AI, Benonisdottir S, Przeworski M, et al.: Deconstructing the sources of genotype-

595   phenotype associations in humans [Internet]. Science (1979) 2019; 365:1396–1400Available

596   from: https://doi.org/10.1126/science.aax3710

 FIGURE CAPTIONS

Figure 1: Sample selection in the All of Us Database

Sample selection for analyses of lifetime risk for substance use disorder (N = 393,596) and within-SUD,

survival PheWAS (N = 21,357). EHR = electronic health records; WGS = whole genome sequence, QC

= quality control.

Figure 2: SUD rates across sociodemographic characteristics and top associations from multivariable

logistic regression.

Bivariate and Adjusted odds ratios (OR) and corresponding 95% confidence intervals presented on the

x-axis. Reference categories indicated by (ref). Adjusted models included all of the social and

demographic risk factors listed in the methods section, simultaneously. Adjusted models also included

covariates for length of EHR and total healthcare utilization.

Figure 3: Survival plots for psychosis and viral hepatis C across SCZ and EXT PGS levels.

Predicted survival curves for psychosis (Panel A) and viral hepatis C (Panel B) as a function of SCZ

and EXT PGS levels, respectively (red = -2 SD, yellow = -1 SD, green = mean, blue = +1 SD, purple =

+2 SD). All models adjusted for age at diagnosis, gender, genetic similarity, first 10 genetic principal

components (PCS), pre-SUD comorbidity burden, and length of EHR.

Table 1: GWAS used input for polygenic score creation

PGS	GWAS outcome	EUR-like N (effective)	AFR-like N (effective)	Refs
AUD PGS	Alcohol use disorder/Problematic alcohol use	257,271	48,015	(43, 44)
CUD PGS	Cannabis use disorder	149,862	61,965	(41)
EXT PGS	Externalizing	1,492,085	99,949	(36, 45)
DEP PGS	Depression	825,811	58,549	(40)
PTSD PGS	Post-traumatic stress disorder	641,533	42,804	(42)
SCZ PGS	Schizophrenia	190,722	36,535	(46, 48)

Table 2: Sample Demographics in All of Us participants with available EHR data and those with a SUD diagnosis

	Full sample (N = 393,596)		SUD sample (N = 42,568)		X^2
	N/Mean	**%/SD**	**N/Mean**	**%/SD**	
Age (mean)	52.36	16.99	50.06	14.63	*
Woman	237,501	60.34%	19,501	45.81%	*
Man	148,918	37.84%	22,009	51.70%	*
Trans and gender non-conforming (TGNC)	3,630	0.92%	434	1.02%	
Asian-American/Pacific Islander	11,714	2.98%	320	0.75%	*
Black/African American	67,197	17.07%	11,769	27.65%	*
Hispanic or Latino/a/x	59,606	15.14%	5,308	12.47%	*
Non-Hispanic White	210,276	53.42%	18,448	43.34%	*
Multiple race-ethnicities	27,177	6.90%	3,667	8.61%	*
Other race-ethnicity not listed	6,134	1.56%	712	1.67%	*
Born outside the US	56,684	14.40%	2,536	5.96%	*
US-born	333,579	91.89%	39,414	92.59%	*
Less than high school	34,773	8.83%	7,036	16.53%	*
High school diploma or GED	74,172	18.84%	13,254	31.14%	*
Some college	102,999	26.17%	12,303	28.90%	*
College graduate	89,340	22.70%	4,918	11.55%	*
Advanced degree	83,228	21.15%	3,402	7.99%	*

619   * $p < .05,$

Table 3: Selected Phenome Wide Significant Association

PGS	Phecode	Description	% Dx	HR	95% CI (low)	95% CI (high)
AUD	317	Alcohol-related disorders	24.40%	1.08	1.05	1.11
CUD	70.3	Viral hepatitis C	13.38%	1.10	1.05	1.15
DEP	599	Other symptoms/disorders or the urinary system	1.84%	1.28	1.15	1.43
DEP	327.5	Parasomnia	1.67%	1.26	1.11	1.43
DEP	411.1	Unstable angina (intermediate coronary syndrome)	2.37%	1.23	1.12	1.36
DEP	301.2	Antisocial/borderline personality disorder	4.73%	1.15	1.07	1.24
DEP	79.9	Viremia, NOS	7.56%	1.12	1.06	1.19
EXT	496.1	Emphysema	8.05%	1.16	1.10	1.23
EXT	70.3	Viral hepatitis C	13.38%	1.15	1.10	1.20
EXT	586.2	Cyst of kidney, acquired	5.08%	1.15	1.07	1.23
EXT	318	Tobacco use disorder	50.10%	1.13	1.11	1.16
EXT	509.8	Dependence on respirator [Ventilator] or supplemental oxygen	5.39%	1.13	1.05	1.21
PTSD	345.1	Epilepsy	3.18%	1.25	1.12	1.39
PTSD	949	Allergies, other	3.84%	1.18	1.07	1.30
PTSD	300.9	Posttraumatic stress disorder	15.27%	1.13	1.08	1.19
PTSD	411.3	Angina pectoris	7.21%	1.13	1.05	1.21
PTSD	496.21	Obstructive chronic bronchitis	9.60%	1.12	1.06	1.19
SCZ	295.2	Paranoid disorders	3.61%	1.30	1.20	1.40
SCZ	295.1	Schizophrenia	8.68%	1.21	1.15	1.28
SCZ	295.3	Psychosis	6.20%	1.21	1.14	1.29
SCZ	306	Other mental disorder	4.13%	1.14	1.06	1.23
SCZ	969	Poisoning by psychotropic agents	3.00%	1.14	1.06	1.24

PGS = polygenic score; AUD = alcohol use disorder; CUD = cannabis use disorder; DEP = depression; EXT = externalizing; PTSD = post-traumatic stress disorder; SCZ = schizophrenia; HR = hazard ratio; CI = confidence interval; % Dx = percent with diagnosis

A — Survival time for Psychosis by SCZ PGS

B — Survival time for Viral hepatitis C by EXT PGS

PRS (SD): —2 — —1 — 0 — 1 — 2